In further preclinical studies, a structurally similar galectin-3 inhibitor, GB1107, inhibited lung adenocarcinoma growth and metastasis, and augmented the tumor response to programmed death-ligand 1 blockade [7]. The gene discussed is LGALS3; the disease is neoplasm.